Pharvaris B.V. PHVS · Stock Open Pharvaris B.V. in new tab
Pharvaris B.V. Analysis (PHVS)
Is Pharvaris B.V. a good investment? Pharvaris B.V. (PHVS) is currently trading at 29.95 USD. Market analysts have a consensus price target of 46.88 USD. This suggests a potential upside from current levels.
Earnings Schedule: Pharvaris B.V. is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -3.08.
Investor FAQ
Does Pharvaris B.V. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Pharvaris B.V.?
Pharvaris B.V. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -3.49.
Company Profile
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Community Discussion